Clincosm LogoSign in Get a demo

refractory acute myeloid leukemia

Showing 76 - 87 of 87
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Advanced Lymphoma, Refractory Lymphoma, Refractory Leukemia Trial in Vienna (Next generation functional drug screening,

Recruiting
  • Advanced Lymphoma
  • +4 more
  • Next generation functional drug screening
  • Comprehensive genomic profiling
  • Vienna, Austria
    Medical University of Vienna
Jul 10, 2020

Refractory Acute Myeloid Leukemia, Relapsed Acute Erythroid Leukemia, Salvage Treatment Trial in Guangzhou (HVA Regimens as

Enrolling by invitation
  • Refractory Acute Myeloid Leukemia
  • +3 more
  • HVA Regimens as Salvage Treatment
  • Guangzhou, Guangdong, China
    Department of Hematology,Nanfang Hospital, Southern Medical Univ
Jun 7, 2020

Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial in San Francisco (Ficlatuzumab,

Terminated
  • Acute Myeloid Leukemia
  • +2 more
  • San Francisco, California
    University of California, San Francisco
Mar 22, 2020

Mixed Phenotype Acute Leukemia, Previously Treated Myelodysplastic Syndrome, Recurrent Adult Acute Myeloid Leukemia Trial in

Completed
Has Results
  • Mixed Phenotype Acute Leukemia
  • +6 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Feb 21, 2020

Acute Biphenotypic Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Recurrent Acute Myeloid

Terminated
Has Results
  • Acute Biphenotypic Leukemia
  • +3 more
  • Houston, Texas
    M D Anderson Cancer Center
Sep 5, 2019

Blasts More Than 5 Percent of Bone Marrow Nucleated Cells, Persistent Disease, Refractory Acute Myeloid Leukemia Trial in

Unknown status
  • Blasts More Than 5 Percent of Bone Marrow Nucleated Cells
  • +2 more
  • Liposome-encapsulated Daunorubicin-Cytarabine
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Aug 6, 2019

Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial (Group 1: TK216, Group 2: TK216, Part 2: Decitabine

Withdrawn
  • Recurrent Acute Myeloid Leukemia
  • Refractory Acute Myeloid Leukemia
  • Group 1: TK216
  • +6 more
  • (no location specified)
May 2, 2019

Refractory Acute Myeloid Leukemia Trial in Pittsburgh (pembrolizumab)

Withdrawn
  • Refractory Acute Myeloid Leukemia
  • Pittsburgh, Pennsylvania
    UPMC Hillman Cancer Center
Apr 17, 2019

Recurrent Adult Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial in Cleveland (ixazomib, mitoxantrone HCl,

Completed
  • Recurrent Adult Acute Myeloid Leukemia
  • Refractory Acute Myeloid Leukemia
  • Cleveland, Ohio
  • +1 more
Dec 12, 2018

Recurrent Adult Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial in Columbus (Azacitidine, Cytarabine, Etoposide

Completed
  • Recurrent Adult Acute Myeloid Leukemia
  • Refractory Acute Myeloid Leukemia
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Sep 20, 2017

Previously Treated Myelodysplastic Syndrome, Recurrent Adult Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial in

Completed
  • Previously Treated Myelodysplastic Syndrome
  • +5 more
  • Columbus, Ohio
  • +1 more
Aug 1, 2017

Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial in Boston (cabozantinib)

Completed
  • Relapsed Acute Myeloid Leukemia
  • Refractory Acute Myeloid Leukemia
  • Boston, Massachusetts
  • +1 more
Jul 18, 2017